Efficacy and tolerance of @entity11797 during long-term treatment of XXXX .

@entity1 @entity1164 @entity1165 @entity11797 @entity2224 @entity943
A group of 51 @entity1 with @entity943 refractory to standard oral antiarrhythmic agents were treated with oral @entity11797 . Antiarrhythmic efficacy was defined as total abolition of occurrences of @entity1165 ( @entity1165 ) or @entity2224 ( @entity2224 ) as assessed by hospital admissions for @entity943 and the occurrence of @entity1164 ( @entity1164 ). Of the 51 @entity1 , 32 (63%) initially tolerated @entity11797 and were discharged from the hospital. Of the 19 @entity1 not initially responding to @entity11797 , 6 (12%) had @entity943 recurrence and 13 (25%) developed intolerable central nervous system or gastrointestinal side effects. Of these 19 short-term nonresponders, 8 (42%) @entity1 suffered @entity1164 over an average follow-up of 24 months (annual @entity1164 rate of 21%). Two @entity1 suffered @entity1164 during the first week of @entity11797 therapy. Discounting the 2 @entity1 with @entity1164 on @entity11797 therapy, 6 of 17 (35%) @entity1 initially withdrawn from @entity11797 suffered @entity1164 (annual @entity1164 rate of 18%). Twenty-four of the 32 short-term responders did not have @entity943 recurrence over a mean follow-up of 38 months resulting in an overall long-term efficacy of 47% (24/51). Over an average follow-up of 38 months for these 24 short-term responders, 12 @entity1 expired from nonarrhythmic causes, 3 @entity1 were withdrawn for non-drug-related causes, and 9 @entity1 remain on @entity11797 therapy. Of the 8 long-term nonresponders, 3 @entity1 had @entity943 recurrence and died suddenly while 5 @entity1 developed intolerable side effects. The annual @entity1164 rate in short-term responders was 3%. Eighteen of the 51 @entity1 (35%) were withdrawn from the study because of adverse effects.(ABSTRACT TRUNCATED AT 250 WORDS)
